Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
Sponsor: Definium Therapeutics US, Inc.
Summary
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
Official title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40 Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Panorama
Key Details
Gender
All
Age Range
18 Years - 74 Years
Study Type
INTERVENTIONAL
Enrollment
250
Start Date
2025-01-29
Completion Date
2027-05
Last Updated
2026-03-13
Healthy Volunteers
No
Conditions
Interventions
Placebo
A substance that is designed to have no therapeutic value
MM120 (LSD D-Tartrate)
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Locations (38)
Preferred Research Partners, Inc.
Little Rock, Arkansas, United States
Psychedelic Science Institute
Los Angeles, California, United States
West Los Angeles VA Medical Center
Los Angeles, California, United States
Cenexel-CNS
Torrance, California, United States
Bradenton Research Center, Inc.
Bradenton, Florida, United States
Clinical Neuroscience Solutions, Inc
Orlando, Florida, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
Sheppard Pratt Health System
Towson, Maryland, United States
Adams Clinical Boston
Boston, Massachusetts, United States
Princeton Medical Institute
Princeton, New Jersey, United States
University of Cincinnati Psychiatry- Anxiety Disorders Research Program
Cincinnati, Ohio, United States
Neuro-Behavioral Clinical Research, Inc.
North Canton, Ohio, United States
Austin Clinical Trial Partners
Austin, Texas, United States
Cedar Clinical Research
Murray, Utah, United States
Core Clinical Research
Everett, Washington, United States
A-shine s.r.o.
Pilsen, Czechia
Institut Neuropsychiatricke Pece (INEP)
Prague, Czechia
Psyon s.r.o.
Prague, Czechia
Cabinet Dr.Desbonnet : Résidence Saint Michel
Douai, France
Hôpital Conception, CIC Centre, bat néphrologie 3eme étage
Marseille, France
CMME
Paris, France
GHU Paris Psychiatrie et Neurosciences
Paris, France
Centre Hospitalier du Rouvray
Sotteville-lès-Rouen, France
Department of Psychiatry and Psychotherapy Campus Charité Mitte Charité Universitätsmedizin Berlin
Berlin, Germany
OVID Clinic Berlin
Berlin, Germany
Central Institute of Mental Health
Mannheim, Germany
Klinik für Psychiatrie und Psychotherapie, Abt: Allgemeine Psychiatrie und Psychotherapie
Tübingen, Germany
Centrum Badan Klinicznych PI-House sp. z o.o.
Gdansk, Poland
Department of Psychiatry, UCK
Gdansk, Poland
Department of Affective and Psychotic Disorders, Central Teaching Hospital, Medical University of Lodz
Lodz, Poland
Neuroclin Glasgow
Glasgow, United Kingdom
Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, St. Nicholas Hospital
Gosforth, United Kingdom
4 Medical Clinical Solutions
London, United Kingdom
Clerkenwell Health - Baker Street
London, United Kingdom
Clerkenwell Health
London, United Kingdom
South London and Maudsley NHS Foundation Trust of The Maudsley Hospital
London, United Kingdom
4 Medical Clinical Solutions
Manchester, United Kingdom
St George's Community Health Centre
Sheffield, United Kingdom